WaveMan
WaveMan · Company
SI · Shoulder Innovations, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SI Shoulder Innovations (SI) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001699350
Quote by TradingView
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
54
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $187.3K priced

What the filings say about SI

Insiders, 180 days
-$5.5M net sold
3 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$5.5M
3 notices

Shoulder Innovations insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, SHOULDER INNOVATIONS, INC. insiders sold a net $5.5M of stock across 148 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Ball Robert Joseph
CEO & Executive Chairman
SELL
2026-09-14 SEC
10,175
$187.7K
+8.0%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Mar 13, 2026.
  • -1.3% median (+3.2% mean) 90-day return after 5 previous buys.
  • The trade is 2.7% of the 380,824 shares held after it.
  • 2 other insiders sold within 30 days.
  • 54 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO & Executive Chairman Ball Robert Joseph sold about $187.7K of SI on Sep 14, 2026; 2 other insiders sold within 30 days and 54 funds added in the latest 13F quarter.
Gilde Healthcare Holding B.V.
SELL
2026-08-28 SECtraded 2026-08-26
1,196
$27.0K
-7.5%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (1 buy, 9 sales), the last on Aug 24, 2026.
  • The trade is 0.1% of the 2,185,914 shares held after it.
  • 2 other insiders sold within 30 days.
  • 54 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Gilde Healthcare Holding B.V. sold about $27.0K of SI on Aug 26, 2026; 2 other insiders sold within 30 days and 54 funds added in the latest 13F quarter.
Gilde Healthcare Holding B.V.
SELL
2026-08-24 SEC
681
$15.4K
-13.2%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (1 buy, 8 sales), the last on Aug 21, 2026.
  • The trade is 0.0% of the 2,187,110 shares held after it.
  • 2 other insiders sold within 30 days.
  • 54 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Gilde Healthcare Holding B.V. sold about $15.4K of SI on Aug 24, 2026; 2 other insiders sold within 30 days and 54 funds added in the latest 13F quarter.
Gilde Healthcare Holding B.V.
SELL
2026-08-24 SECtraded 2026-08-21
20,516
$463.9K
-13.2%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (1 buy, 7 sales), the last on Aug 20, 2026.
  • The trade is 0.9% of the 2,187,791 shares held after it.
  • 2 other insiders sold within 30 days.
  • 54 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Gilde Healthcare Holding B.V. sold about $463.9K of SI on Aug 21, 2026; 2 other insiders sold within 30 days and 54 funds added in the latest 13F quarter.
Gilde Healthcare Holding B.V.
SELL
2026-08-24 SECtraded 2026-08-20
3,900
$88.1K
-13.2%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (1 buy, 6 sales), the last on Aug 6, 2026.
  • The trade is 0.2% of the 2,208,307 shares held after it.
  • 2 other insiders sold within 30 days.
  • 54 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Gilde Healthcare Holding B.V. sold about $88.1K of SI on Aug 20, 2026; 2 other insiders sold within 30 days and 54 funds added in the latest 13F quarter.
148 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 143 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$5.5M over 180 days
-$5.1M over 90 days · -$4.4M of it by a 10%+ holder
below 79% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
54 funds bought in last quarter
below 56% of Medical Devices
Revenue
+49.6% year over year
more than 86% of Medical Devices
Margin
-85.3% net margin
below 78% of Medical Devices
Buybacks
no share repurchases reported
Short interest
3.0% of shares outstanding short · 3.9 days to cover · settled 2026-09-30
below 55% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch SI

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+54.3%12M
-12%+23%+58%+93%2025-102025-122026-022026-042026-062026-082026-10 2026-08-04 · Gilde Healthcare Holding B.V. sold $2.3M2026-07-30 · Gilde Healthcare Holding B.V. sold $659.8K2026-08-21 · Gilde Healthcare Holding B.V. sold $463.9K2026-07-31 · Gilde Healthcare Holding B.V. sold $455.4K2026-06-12 · Ahearn Matthew Fraser sold $296.2K2026-08-18 · Ahearn Matthew Fraser sold $263.5K2026-08-03 · Gilde Healthcare Holding B.V. sold $244.2K2026-09-14 · Ball Robert Joseph sold $187.7K2026-08-17 · Ahearn Matthew Fraser sold $167.1K2026-08-05 · Gilde Healthcare Holding B.V. sold $166.1K2026-08-20 · Gilde Healthcare Holding B.V. sold $88.1K2025-12-12 · Ball Robert Joseph bought $58.1K2025-12-11 · Ball Robert Joseph bought $48.9K2026-06-15 · Ahearn Matthew Fraser sold $48.2K2026-08-06 · Gilde Healthcare Holding B.V. sold $47.3K2026-08-18 · Ahearn Matthew Fraser sold $34.2K2026-03-13 · Ball Robert Joseph bought $33.4K2026-03-13 · Points Jeffrey S. bought $30.0K2026-06-15 · Ahearn Matthew Fraser sold $29.9K2026-08-26 · Gilde Healthcare Holding B.V. sold $27.0K2026-08-24 · Gilde Healthcare Holding B.V. sold $15.4K2025-12-12 · Points Jeffrey S. bought $15.1K2026-03-13 · Buchholz Richard bought $14.8K2025-12-11 · Points Jeffrey S. bought $14.6K2026-09-14 · ROBERT BALL filed to sell $187.7K2026-08-17 · MATTHEW AHEARN filed to sell $466.4K2026-07-29 · Gilde Healthcare Holding B.V.; Cooperatieve Gilde Healthcare V U.A. filed to sell $4.8M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SI: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
3,673,960 sh
$74.5M
BlackRock, Inc.
638,420 sh
$12.9M
SECTORAL ASSET MANAGEMENT INC
430,407 sh
$8.7M
VANGUARD CAPITAL MANAGEMENT LLC
392,181 sh
$8.0M
KCM Capital Inc
300,000 sh
$6.1M

Congress trades in SI

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SI planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
ROBERT BALL
Filed 2026-09-14
$187.7K
MATTHEW AHEARN
Filed 2026-08-17
$466.4K
Gilde Healthcare Holding B.V.; Cooperatieve Gilde Healthcare V U.A.
Filed 2026-07-29
$4.8M

SI mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Select Medical Technology and Devices Portfolio
$13.9M position · as of 2026-05-31
0.5%
AMG TimesSquare Small Cap Growth Fund
$325.3K position · as of 2026-06-30
0.3%
Fidelity Advisor Health Care Fund
$7.1M position · as of 2026-07-31
0.2%
Fidelity Small Cap Growth Fund
$17.7M position · as of 2026-07-31
0.2%
Fidelity Small Cap Growth K6 Fund
$8.8M position · as of 2026-07-31
0.2%
Select Health Care Portfolio
$8.0M position · as of 2026-05-31
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $5.5M sold by insiders over 180 days, 54 funds added last quarter, $5.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

SI financials

Revenue growth
+49.6%
XBRL, annual
Net margin
-85.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$60.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-58.3%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$47.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.12x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-2.50x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-151.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-30.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-34.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
23.93x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$393.8M
market value at close 2026-10-26 on 2026-07-30 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-11.7%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-12
Revenue$47.3M$31.6M
Gross profit$36.2M$24.3M
Operating income-$26.3M-$14.7M
Net income-$40.4M-$15.6M
EPS (diluted)-4.65-242.04
Operating cash flow-$28.6M-$14.1M
Cash$26.9M$6.1M
Long-term debt$14.9M$14.7M
SEC XBRL, fiscal years, as known on 2026-10-28

SI Stock Sonar score 6/7 axes

Find similar shapesCompare

SI ranks highest on growth (86th percentile) and risk and compliance (63rd), and lowest on insider conviction (10th), among Medical Devices peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
32
Inputs
  • Return on equity-151.9% · 19 pct, sector of 183
  • Return on assets-30.5% · 40 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-34.4% · 38 pct, sector of 188
Financial health
43
Inputs
  • Debt to equity0.12x · 65 pct, sector of 159
  • Cash flow to debt-2.50x · 20 pct, sector of 150
Growth
86
Inputs
  • Revenue growth, YoY+49.6% · 86 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
10
Inputs
  • Net Form 4 buying (codes P and S), 180d-$5.5M · 20 pct, sector of 140
  • Insider buyers, 180d0 · 0 pct, sector of 142
Institutional and government
44
Inputs
  • Funds adding, latest quarter54 · 44 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
63
Inputs
  • Short interest, % of shares outstanding (no float on file)+3.0% · 63 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

SI filings, in plain words

Are Shoulder Innovations insiders buying or selling SI?

In the 180 days to 2026-10-28, Shoulder Innovations insiders were net sellers, a net $5.5M across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of SI?

Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $5.5M of stock; the latest, by ROBERT BALL, was filed 2026-09-14.

Read the full summary

In the 180 days to 2026-10-28, Shoulder Innovations insiders were net sellers of SI, a net $5.5M across purchases and sales reported on Form 4 by 3 sellers. Most of that figure, $4.4M, came from a holder of 10% or more rather than an officer or director. None of the 17 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $5.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies